Yet Another Drug Company Sues to Stop Medicare from Negotiating Lower Drug Prices

Schweikert Voted Against Inflation Reduction Act, Supports Plan to Eliminate Drug Price Negotiation

PHOENIX — The Inflation Reduction Act's wildly popular Medicare drug price negotiation provision is under attack from Republicans in Congress like David Schweikert who voted against it, as well as pharmaceutical companies who are now suing to overturn the law.

The drug manufacturer, Novartis, filed suit in the Ninth Circuit to overturn the law this week after the Biden administration announced that one of its medications—heart failure drug Entresto—would be targeted for price negotiation.

Schweikert, who sits on the Republican Study Committee, supported a budget released this summer that would undermine Medicare’s ability to negotiate drug prices.

“Congressman Schweikert is putting the interests of Big Pharma ahead of his constituents by threatening to undermine Medicare’s ability to negotiate the cost of prescription drugs,” said Honest Arizona executive director Andrea Moreno. “The Inflation Reduction Act lowers health care costs for Arizonans, but if Schweikert gets his way, hundreds of thousands of Arizona seniors will keep paying too much for their medication.”

###